Researchers say ocrelizumab may diminish the immune response in people with multiple sclerosis who receive vaccines for tetanus, seasonal flu, and pneumococcus.
One year after its approval, experts continue to study the impact of ocrelizumab, the first drug for progressive multiple sclerosis.
One study found some diminished vaccine responses in people taking ocrelizumab, sold under the brand name Ocrevus.
Another study is finding new insights into biological markers within the central nervous system for people with multiple sclerosis (MS).
The findings of these two studies were presented at the 2018 American Academy of Neurology (AAN) annual meeting in Los Angeles by Dr. Amit Bar-Or, FRCPC, chief of the multiple sclerosis division and director of the Center for Neuroinflammation and Experimental Therapeutics at Penn Medicine.
The effect on vaccines
The VELOCE study looked at the response of ocrelizumab patients to vaccines for tetanus, seasonal flu, and pneumococcus.
Comparisons were made between those who were treated with ocrelizumab and those who were not. Also taken into consideration was the timing of the vaccine in association with the treatment.
Patients who had the tetanus vaccine while also taking ocrelizumab showed a 24 percent immune response, whereas those who only had the tetanus vaccine showed 55 percent.
The flu vaccine showed a decrease in immune response from 100 percent to 71 percent for those treated with ocrelizumab, compared to those who weren’t taking the medication.
The study shows that while patients who receive ocrelizumab can still mount immune responses to many types of vaccines, the vaccine responses are diminished,” Bar-Or told Healthline.
“The suggestion is to have key vaccines up to date, prior to starting ocrelizumab,” said Bar-Or. “It is useful to speak with the treating team about vaccine status prior to starting ocrelizumab.”
“There is no reason to think that tetanus vaccine (or other vaccines) will generate a less potent or less durable vaccine response in someone just because they have MS. However, certain MS treatments (which may work by diminishing the potency of certain immune responses) may result in less potent vaccine responses,” explained Bar-Or.
“Since vaccine responses normally wear out gradually over a while (usually quite a few years), if the original magnitude of the vaccine response was diminished due to patient being on an immune therapy, then the effect of the vaccine may wear out sooner,” he noted.
Bruce Bebo, executive vice president of research at the National Multiple Sclerosis Society, simplified the vaccine process.
“Vaccines target B cells, turning them into memory cells that hide out until needed,” he told Healthline.
Ocrelizumab targets B cells, which is why the vaccine response is affected.
“There is still a response, but is it strong enough to be effective? Nobody knows yet,” said Bebo. “We are learning the consequences of these kinds of therapies. Kudos to the company and Bar-Or for doing the study to understand all the ramifications.”
The second paper presented was an interim report of an ongoing biomarker study.
The OBOE biomarker study shows that the level of neurofilament in the spinal fluid of patients (a measure of injury to the axons and neurons) is substantially reduced soon after treatment with ocrelizumab,” Bar-Or told Healthline.
“Providing new insights into the importance of B cell-T cell interaction and their apparent contribution to [central nervous system] injury within the [central nervous system] of MS patients helps understand the relationship between processes occurring outside versus inside the [central nervous system],” explained Bar-Or. “And it provides framework for further understanding and developing directed treatments for the [central nervous system] processes that likely contribute importantly to ongoing [central nervous system] injury in people with MS.”
Bebo explained that when certain proteins are found inside a neuron it means there is damage. Released only when the neuron is damaged, these proteins can be measured in spinal fluid and blood tests.
“Having a biomarker that can help follow disease progression or activity is a big advance for MS. Neurofilament is leading biological biomarker for monitoring disease progression and potentially response to therapy, but not necessarily diagnoses,” said Bebo.
The OBOE study is still underway with additional results expected next year.
The research work was supported by Genentech, developers of ocrelizumab.
The second study presented by Bar-Or is sponsored by F. Hoffmann-La Roche Ltd., the holding company for Genentech.